An isolated strain of Enterococcus faecalis GALT deposited under number C E C T 7121 of the group of lactic bacteria is disclosed, which is capable of surviving and colonizing the gastrointestinal tract of humans and/or animals and showing beneficial probiotic activity for the health of humans and animals. The strain E. faecalis GALT and/or a culture supernatant and/or metabolites thereof shows no in vitro multiresistance to antibiotics of common use in human clinics as glycopeptides, such as vancomycin, teicoplanine； carbapenemes, such as impipenem, meropenem； and ampicillin. The strain E. faecalis GALT contains no red blood cell-destroying hemolysins of human, ovine and equine origin； and it does not produce any gelatinase, DNase and decarboxylases. The strain E. faecalis GALT is useful for the preparation of a composition intended for the treatment and/or prophylaxis of disorders associated with colonization by pathogenic microorganisms of the gastrointestinal tract； for use as a regulator of the immune response in human and animals, as well as for the preparation of a composition. The invention is also directed to methods and uses of the strain E. faecalis GALT.
